Drug details

Pharmorubicin (epirubicin)

type of Antineoplastics, Anthracycline

Pharmorubicin CS (epirubicin hydrochloride) is indicated for the treatment of breast cancer, gastric cancer, ovarian cancer, small cell lung cancer, lymphoma (non-Hodgkin’s lymphoma), advanced/metastatic soft tissue sarcoma, and superficial bladder cancer (Tis; Ta). In bladder cancer, Pharmorubicin is also indicated in the prophylaxis of recurrence after transurethral resection of stage T1 papillary cancers and stage Ta multifocal papillary cancers (Grade 2 and 3).

This drug may have the following side effects:

• nausea,
• vomiting,
• diarrhea,
• redness, ulcers, and, bleeding of mucus membranes,
• hair loss (usually reversible),
• red streaking along the infused vein, and
• dehydration.

The following drugs are related to Pharmorubicin, either as a replacement or used together:

• Abraxane (albumin-bound paclitaxel for injectable suspension)
• Afinitor (everolimus tablets)
• Arimidex (anastrozole)
• Aredia (pamidronate disodium)
• Aromasin (exemestane)
• Ellence (epirubicin hydrochloride)
• Enhertu (fam-trastuzumab deruxtecan-nxki for injection)
• Evista (raloxifene)
• Soltamox (tamoxifen citrate)